The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step FDA to weigh easing limits on unproven peptides The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and The trend of unproven peptides is spreading through influencers and RFK Jr. allies CNN